Orgenesis Inc.
Biotechnology company developing a point-of-care (POCare) platform for decentralized cell and gene therapy manufacturing, including CAR-T and regenerative medicine products.
- CEO / Founder
- Vered Caplan
- Team Size
- 51-200 employees
- Stage
- Public
- Total Funding
- $50M
- Latest Round
- Post-IPO
- Key Investors
- Metalmark Capital; Great Point Partners; The Phoenix Insurance Company Ltd.; Sphera Global Healthcare Master Fund; Jacob Safier; Wallonia Regional Government
Technology & Products
Key Products
Octomera point-of-care platform; POCare Center network; CDMO manufacturing services; ORG-101 CAR-T therapy; Cell therapy development programs
Technological Advantage
Orgenesis claims its POCare platform decentralizes cell and gene therapy production by embedding GMP-grade manufacturing into hospital settings, supported by proprietary transdifferentiation technology developed by founder Dr. Sarah Ferber. The company has received patents for its Type 1 diabetes approach and acquired CDMO MaSTherCell to bolster manufacturing capabilities. While the decentralized model creates partner switching costs and regulatory know-how, the core manufacturing processes are replicable by larger contract development organizations.
Differentiation
Value Proposition
Enables hospitals to produce cell and gene therapies on-site via the POCare platform, reducing manufacturing turnaround times and logistics costs while enabling personalized treatment at scale.
How They Differentiate
Orgenesis differentiates by enabling decentralized, point-of-care manufacturing of cell and gene therapies, reducing costs by up to 50% and turnaround time by 30-50% compared to centralized CDMOs like Lonza and Catalent. Their POCare platform is installed at hospital sites, eliminating cryopreservation and shipping logistics, and enabling autologous therapies to be produced on-demand.
Market & Competition
Target Customers
Hospitals and academic medical centers; biopharmaceutical companies outsourcing cell/gene therapy manufacturing; life science researchers
Industry Verticals
Cell Therapy; Gene Therapy; Regenerative Medicine; Biopharmaceutical Manufacturing
Competitors
Lonza Group; Cellares; Catalent
Growth & Milestones
Growth Metrics
Q2 2022 revenue $7.20M, -31.71% Y/Y (Seeking Alpha). csimarket.com: shares outstanding ~4M, employees 77, revenues TTM ~$1M, net income TTM ~$49M. 10-K indicates no revenue milestones for 2022/2023.
Major Milestones
2008: Founded; 2011: Merged with Orgenesis Inc. (Nevada); 2013: Sav DiPasquale appointed CEO; 2014: Vered Caplan appointed CEO; 2015: Acquired MaSTherCell; 2022: $14.8 million private placement; 2024: Added UC Davis to POCare network; 2025: Secured ~$5M funding for CGT initiatives
Notable Customers
UC Davis; Cure Therapeutics
Funding rounds
- Debt$1.5M2024-08Source: BioSpace
- Post-IPO$5M2023-05Lead: Metalmark Capital · Source: GlobeNewswire
- Post-IPO$750K2023-05Lead: Jacob Safier · Source: Investing.com
- Post-IPO$3.7M2023-02Source: FirstWord Pharma
- Post-IPO$50M2022-11Lead: Metalmark Capital · Source: GlobeNewswire